Ralphey, I don't think you can extrapolate a buyout valuation based on the current stock price. When I was a younger man the market had a predictive value. People would buy and sell based on what they thought would happen in the future. We now have all time high market valuation during a pandemic that has crippled our economy. We have food lines, massive unemployment, people loosing there homes, political division, and no end in sight. When I try to rap my mind around what our company is worth I go to potential revenue. I think most of us agree that Amarin lacks the resources to reach Vascepa's full potential. Last year global statin sales were nearly 1 trillion dollars. Any patient on a statin should also be on Vascepa. I think that potential is worth more than a 45 percent premium to our share price.
Sleven,
News 
Market Data 
Discover 
AI
